Back to top
more

Phibro Animal Health (PAHC)

(Real Time Quote from BATS)

$22.35 USD

22.35
14,101

+0.20 (0.90%)

Updated Sep 19, 2024 10:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

TMO Stock to Gain From Expanded Bioanalytical Services in Sweden

Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PAHC vs. ABT: Which Stock Is the Better Value Option?

PAHC vs. ABT: Which Stock Is the Better Value Option?

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA

Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.

Is Phibro Stock Worth Retaining in Your Portfolio Now?

PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.

PAHC Stock Gains From Innovation, Market Expansion Goal

Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are You Looking for a Top Momentum Pick? Why Phibro Animal Health (PAHC) is a Great Choice

Does Phibro Animal Health (PAHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Implied Volatility Surging for Phibro Animal Health (PAHC) Stock Options

Investors need to pay close attention to Phibro Animal Health (PAHC) stock based on the movements in the options market lately.

PAHC vs. ABT: Which Stock Should Value Investors Buy Now?

PAHC vs. ABT: Which Stock Is the Better Value Option?

Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Phibro (PAHC) International Revenue Performance Explored

Examine the evolution of Phibro's (PAHC) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.

Here's What Key Metrics Tell Us About Phibro (PAHC) Q4 Earnings

While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phibro Animal Health (PAHC) Beats Q4 Earnings and Revenue Estimates

Phibro (PAHC) delivered earnings and revenue surprises of 20.59% and 4.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Phibro (PAHC) Stock Jumps 10.2%: Will It Continue to Soar?

Phibro (PAHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Countdown to Phibro (PAHC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Besides Wall Street's top -and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

ICU Medical, Inc. (ICUI) Hits Fresh High: Is There Still Room to Run?

ICU Medical (ICUI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Phibro Animal Health (PAHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Phibro (PAHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quipt Home Medical Corp. (QIPT) Reports Q3 Loss, Lags Revenue Estimates

Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -500% and 1.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Cardinal Health (CAH) in Q4 Earnings?

Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.

Warby Parker Inc. (WRBY) Beats Q2 Earnings and Revenue Estimates

Warby Parker (WRBY) delivered earnings and revenue surprises of 20% and 0.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?